StockGuild

$IDXG On a Clear Breakout with Potential News Down Pipeline

Long
NASDAQ:IDXG   None
$IDXG Latest Insider Purchases, Institutional Ownerships and News:

2016-02-03 Glorikian Harry Director Acquired 127,696
2016-02-03 KEEGAN JOSEPH D Director Acquired 127,696
2016-02-03 STOVER JACK E Interim President and CEO Director Acquired 294,756
2016-02-03 SULLIVAN STEPHEN J Director Acquired 295,656
2017-06-23 SC 13G ARMISTICE CAPITAL, LLC Acquired 965,784

John P. Dugan (Founder): 4,869,878 common shares

Other Insiders Approximately: 2,672,149 shares collectively

Total Insiders: 7,542,027 shares

Institutional Ownership: 30.6% 5.5 mil shares (Increased to 6.5 mil as of June 23rd)


Largest Institutional Holder: Heartland Advisors: 2,994,313


Recent News Headlines:

2017-06-28 Interpace Diagnostics Announces National Contract With Aetna

2017-06-26 Interpace Diagnostics Announces Coverage Of Thyroid Test By Premera Blue Cross

2017-06-16 Interpace Diagnostics Announces Pricing Of $13.7 Million Underwritten Public Offering Of Common Stock And Common Warrants

2017-06-06 Interpace Diagnostics Announces Agreement With Einstein Medical Center Of Philadelphia

2017-05-25 Interpace Diagnostics Announces Launch Of Enhancement To Thyroid Testing Services

2017-05-16 Interpace Diagnostics Group's (IDXG) CEO Jack Stover on Q1 2017 Results - Earnings Call Transcript

2017-05-15 Interpace Diagnostics To Host Conference Call And Webcast To Discuss First Quarter 2017 Financial Results On Monday May 15, 2017

2017-05-10 Interpace Diagnostics Presents New Data on PancraGEN® at DDW

2017-04-20 Interpace Diagnostics Eliminates Long Term Secured Debt

2017-04-18 Interpace Diagnostics Announces Coverage Of ThyraMIR With UnitedHealthcare

2017-04-13 Interpace Diagnostics Announces Receipt of Letter From Nasdaq Confirming Compliance With Minimum Stockholders' Equity Requirement

2017-04-04 A Look at Interpace Diagnostics Financials, Drug Pipeline and Market Opportunity

2017-04-03 Interpace Diagnostics Announces European Patent Approval For Underlying Technology Of Its Thyramir Microrna Classifier

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.